Enhanced interleukin production after long-term administration of erythromycin stearate.
The effects of erythromycin stearate (10 mg/kg/day) were studied on productions of interleukin (IL)-1 and -2 in mice after a long-term treatment. A 28-day treatment resulted in higher levels of IL-1 production by macrophages and of IL-2 production by splenocytes, while a 7-day treatment did not increase them. T-cell growth factor activity of IL-2 preparation prepared on day 28 of treatment as determined by HT-2 cell proliferation was reduced by about 40% in the presence of anti-murine IL-4 monoclonal antibodies, while control IL-2 activity was not reduced. Furthermore, a 28-day treatment with erythromycin stearate increased concanavalin A-induced blastogenesis of splenocytes significantly. These results suggest that long-term treatment with erythromycin stearate can stimulate host defense by increasing interleukin production.
Kita
E
E
Department of Bacteriology, Nara Medical University, Japan.
Sawaki
M
M
Nishikawa
F
F
Mikasa
K
K
Yagyu
Y
Y
Takeuchi
S
S
Yasui
K
K
Narita
N
N
Kashiba
S
S
D000818:Animals; D002981:Clindamycin / Q000494:pharmacology; D004917:Erythromycin / Q000031:analogs & derivatives* / Q000494:pharmacology; D005122:Exudates and Transudates / Q000276:immunology; D005260:Female; D007375:Interleukin-1 / Q000096:biosynthesis*; D007376:Interleukin-2 / Q000096:biosynthesis*; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D008809:Mice, Inbred C3H; D008815:Mice, Inbred Strains; D013154:Spleen / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D013601:T-Lymphocytes / Q000187:drug effects / Q000378:metabolism
D007375:Interleukin-1; D007376:Interleukin-2; D002981:Clindamycin; D004917:Erythromycin; C011462:erythromycin stearate